Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled study of BAN2401 in mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease
jRCT2080222490Phase 1
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability of repeated BAN2401 intravenous infusions, Pharmacokinetics of BAN2401 and 2 more.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080222490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222490.